Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever.
Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes
June 3, 2024 Australian Biotech
Latest Video
New Stories
-
New data uncovers our most painful moments as access to treatment expands
June 2, 2025 - - Latest News -
Australian innovation could revolutionise the early detection of ovarian cancer
June 2, 2025 - - Latest News -
AusBiotech welcomes shadow ministry and encourages bipartisan support for life sciences sector
June 2, 2025 - - Latest News -
Radiopharm Theranostics reports Preclinical Lu177-B7H3-mAb data
June 2, 2025 - - Australian Biotech -
Neurotech announces positive human PK study results for NTI164
June 2, 2025 - - Australian Biotech -
Cardiex receives TGA approval for CONNEQT Pulse arterial health monitor
June 2, 2025 - - Australian Biotech -
Pharmac minister sworn in as New Zealand's Deputy Prime Minister
June 1, 2025 - - Latest News